capital increase of Baht 55 million. Please be informed accordingly. Sincerely yours, Miss Suwarin Konthong Executive Vice President of Account and Finance DOD Biotech Public Company Limited

debt ratio stemming from increased loans and lower shareholder equity, the ratio was nonetheless at comfortably low level. The interest coverage ratio (EBITDA / finance costs) decreased to 53.7x from

) (32,536) -10% Impairment of investment in subsidiary - - (3,723) - 100% Finance costs (28,569) (33,716) -15% (13,738) (19,474) -29% 4 THB’000 Consolidated ∆% Separate ∆% 1Q2019 1Q2018 1Q2019 1Q2018 Profit

Financial Statements is attached herewith for your acknowledgement and disseminating to investors accordingly. Yours Sincerely, ( Kamtorn Sila-On ) President Production and Finance S & P Syndicate Public

) 10.8% (146.1) (187.4) (41.3) 28.3% Operating Profit 190.4 217.7 27.3 14.4% 377.5 452.2 74.8 19.8% Finance Cost (30.6) (45.4) (14.8) 48.4% (58.3) (86.5) (28.2) 48.3% Tax Expenses (39.3) (35.1) 4.2 -10.7

last year.  Finance Cost The Company and its subsidiaries had the financial cost 0.9 MB in Q2/2019 which decreased by 1.3 MB from Q2/2018 or 58.0 percent (2.2 MB in Q2/2018) Financial Status The overall

& Admin. Expenses 277,383 217,667 59,716 27.43 580,981 474,685 106,296 22.39 Finance cost 82,670 70,310 12,360 17.58 160,189 143,063 17,126 11.97 Net profit 131,254 126,434 4,820 3.81 258,860 170,917 87,943

-100% Other income 7,251 3,503 107% 13,922 18,667 -25% Selling expenses (114,508) (82,176) 39% (202,631) (188,373) 8% Administrative expenses (78,114) (77,391) 1% (149,610) (175,229) -15% Finance costs

-sale investments decreased 106.78 Million Baht, finance lease receivables decreased 15.43 Million Baht, investment in associated companies decreased 27.06 Million Baht, fixed assets decreased 42.83

% - - 433 100.00% Share of profit (loss) from investment in joint venture - - 355 0.09% (355) (100.00%) Finance cost (8,318) 1.58% (8,290) 2.06% (28) (0.34%) Profit (Loss) before income tax income (expenses